GE forms JV to develop compact cyclotron production operations
GE Healthcare and NXT2B, a privately-owned venture capital company, have entered into a joint financing agreement with the goal of developing a micro-scale radiotracer infrastructure, including cyclotron and PET tracer production. The three-year development project, which will be led by GE and based in Uppsala, Sweden, will aim to develop the turnkey radiotracer infrastructure for the production of PET tracers to fulfill the needs of emerging markets, for rural and regional hospitals, and researchers.
GE's newly-developed TRACERcenter 600 is a cyclotron system, whilst the PETtrace 600 is a a radiotracer production operation system that is designed to be accommodated in additional settings. Together with PETtrace 600, TRACERcenter 600 will be capable of producing a full portfolio of F18 and C11 tracers to detect cancer and neurodegenerative disease.